With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...
Tech stocks and top consumer names are increasingly at risk of steep declines in a slowing economy. Click here to see 5 ...
Former India coach Ravi Shastri has urged Virat Kohli to quickly regain his form after the star batter struggled in the ongoing ODI series against Australia. Kohli, returning to international cricket ...
This article was reviewed by Knox Beasley, MD. Rogaine vs Minoxidil: What’s Best for Hair Growth? Growing up, you may have ...
Arne Slot has played down Mohamed Salah’s slow start to season but admitted Liverpool’s adjustment to life without Trent Alexander-Arnold could be a factor. Salah, 33, was dropped for a second ...
As they have for the past 25-plus years, the Cleveland Browns remain in quarterback purgatory, and that's where the New England Patriots were just a few years ago. Now, they have one of the brightest ...
Hosted on MSN
The unseen Kieran Tierney Celtic drive shown to team-mates will see star find best form
Scott Allan got an early insight into Kieran Tierney ’s drive as a member of the same car pool making the daily trip to Lennoxtown. That was a decade ago when he was in his first season with Celtic ...
Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.
Vertex Pharmaceuticals reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis treatments and early contributions from newer ...
Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.58 per share, up from $4.38 per share in the year-ago period. The consensus estimate for Vertex ...
The Green Bay Packers have real questions at cornerback right now. The team invested heavily in free agent Nate Hobbs during the offseason. Thus far, Hobbs has struggled with injuries and inconsistent ...
Advocacy groups form a buyer’s club to obtain generic versions of pricey Vertex cystic fibrosis drug
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback